Sophiris Bio, a PE-backed biotech, priced its IPO at $5 per share and went public. Its shares now trade on the NASDAQ as SPHS. The pricing was well below announced expectations of $13 per share, but the company boosted the number of shares offered from 5 million to 13 million. Sophiris Bio is developing a clinical-stage, targeted treatment for enlarged prostate. Warburg Pincus owned a 27.8% pre-IPO stake in the company, Canadian VC firm BC Advantage Funds owned a 6.6% share and Tavistock Group owned 30.5%. Originally founded in Vancouver, the company already trades on the TSX exchange. It closed its NASDAQ debut at $4.15.